Decitabine enhances targeting of AML cells by NY-ESO-1-specific TCR-T cells and promotes the maintenance of effector function and the memory phenotype
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Decitabine enhances targeting of AML cells by NY-ESO-1-specific TCR-T cells and promotes the maintenance of effector function and the memory phenotype
Authors
Keywords
-
Journal
ONCOGENE
Volume 41, Issue 42, Pages 4696-4708
Publisher
Springer Science and Business Media LLC
Online
2022-09-13
DOI
10.1038/s41388-022-02455-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming
- (2021) Yao Wang et al. Nature Communications
- Selection of initial therapy for newly-diagnosed adult acute myeloid leukemia: Limitations of predictive models
- (2020) Roland B. Walter et al. BLOOD REVIEWS
- CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions
- (2020) Sherly Mardiana et al. Frontiers in Oncology
- Decitabine-Mediated Epigenetic Reprograming Enhances Anti-leukemia Efficacy of CD123-Targeted Chimeric Antigen Receptor T-Cells
- (2020) Liangshun You et al. Frontiers in Immunology
- T cell receptor-engineered T cells for leukemia immunotherapy
- (2019) Yikai Zhang et al. Cancer Cell International
- High-affinity T cell receptors redirect cytokine-activated T cells (CAT) to kill cancer cells
- (2019) Synat Kang et al. Frontiers of Medicine
- T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant
- (2019) Aude G. Chapuis et al. NATURE MEDICINE
- Immunotherapy for acute myeloid leukemia (AML): a potent alternative therapy
- (2018) Desmond O. Acheampong et al. BIOMEDICINE & PHARMACOTHERAPY
- Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
- (2018) Joseph A. Fraietta et al. NATURE MEDICINE
- Chimeric Antigen Receptor Therapy
- (2018) Carl H. June et al. NEW ENGLAND JOURNAL OF MEDICINE
- CAR T cell immunotherapy for human cancer
- (2018) Carl H. June et al. SCIENCE
- Mechanisms of immune escape after allogeneic hematopoietic cell transplantation
- (2018) Robert Zeiser et al. BLOOD
- Lentiviral transduction of mammalian cells for fast, scalable and high-level production of soluble and membrane proteins
- (2018) Jonathan Elegheert et al. Nature Protocols
- Isolation and characterization of NY-ESO-1–specific T cell receptors restricted on various MHC molecules
- (2018) Michael T. Bethune et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
- (2017) Terry J Fry et al. NATURE MEDICINE
- CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
- (2016) Cameron J. Turtle et al. JOURNAL OF CLINICAL INVESTIGATION
- Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy
- (2016) Pragya Srivastava et al. Oncotarget
- Generation of CD20-specific TCRs for TCR gene therapy of CD20low B-cell malignancies insusceptible to CD20-targeting antibodies
- (2016) Lorenz Jahn et al. Oncotarget
- Efficiency of high-dose cytarabine added to CY/TBI in cord blood transplantation for myeloid malignancy
- (2015) Y. Arai et al. BLOOD
- Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses
- (2015) Katherine B. Chiappinelli et al. CELL
- Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts
- (2015) Pragya Srivastava et al. Epigenetics
- Selection bias: maintaining less-differentiated T cells for adoptive immunotherapy
- (2015) Yang Xu et al. JOURNAL OF CLINICAL INVESTIGATION
- NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma
- (2015) Aaron P Rapoport et al. NATURE MEDICINE
- Treatment with 5-Aza-2'-Deoxycytidine Induces Expression of NY-ESO-1 and Facilitates Cytotoxic T Lymphocyte-Mediated Tumor Cell Killing
- (2015) Agnes S. Klar et al. PLoS One
- Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15
- (2014) Y. Xu et al. BLOOD
- A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1-Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response
- (2014) P. F. Robbins et al. CLINICAL CANCER RESEARCH
- Methylation of NKG2D ligands contributes to immune system evasion in acute myeloid leukemia
- (2014) A Baragaño Raneros et al. GENES AND IMMUNITY
- Single and Dual Amino Acid Substitutions in TCR CDRs Can Enhance Antigen-Specific T Cell Functions
- (2014) Paul F. Robbins et al. JOURNAL OF IMMUNOLOGY
- Sequential Treatment with Cytarabine and Decitabine Has an Increased Anti-Leukemia Effect Compared to Cytarabine Alone in Xenograft Models of Childhood Acute Myeloid Leukemia
- (2014) Sarah M. Leonard et al. PLoS One
- Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer
- (2014) K. Odunsi et al. Cancer Immunology Research
- Graft-Versus-Host Disease and Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation
- (2013) Rainer Storb et al. JOURNAL OF CLINICAL ONCOLOGY
- The cancer-testis antigen NXF2 is activated by the hypomethylating agent decitabine in acute leukemia cells in vitro and in vivo
- (2013) JIHAO ZHOU et al. Molecular Medicine Reports
- Increased PRAME-Specific CTL Killing of Acute Myeloid Leukemia Cells by Either a Novel Histone Deacetylase Inhibitor Chidamide Alone or Combined Treatment with Decitabine
- (2013) Yushi Yao et al. PLoS One
- Epigenetic induction of adaptive immune response in multiple myeloma: sequential azacitidine and lenalidomide generate cancer testis antigen-specific cellular immunity
- (2012) Amir A. Toor et al. BRITISH JOURNAL OF HAEMATOLOGY
- Transient Low Doses of DNA-Demethylating Agents Exert Durable Antitumor Effects on Hematological and Epithelial Tumor Cells
- (2012) Hsing-Chen Tsai et al. CANCER CELL
- Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors
- (2012) Emmet McCormack et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Epigenetic Modulation to Enable Antigen-specific T-cell Therapy of Colorectal Cancer
- (2012) Jeffrey Chou et al. JOURNAL OF IMMUNOTHERAPY
- Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia
- (2011) Djordje Atanackovic et al. AMERICAN JOURNAL OF HEMATOLOGY
- Tumor Evasion from T Cell Surveillance
- (2011) Katrin Töpfer et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1
- (2011) Paul F. Robbins et al. JOURNAL OF CLINICAL ONCOLOGY
- CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors
- (2011) S Negrotto et al. LEUKEMIA
- Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia
- (2010) O. Goodyear et al. BLOOD
- The DNA demethylating agent 5-aza-2′-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells
- (2010) Maika Almstedt et al. LEUKEMIA RESEARCH
- Cancer/testis (CT) antigens: Potential targets for immunotherapy
- (2009) Otavia L. Caballero et al. CANCER SCIENCE
- Intertumor and Intratumor NY-ESO-1 Expression Heterogeneity Is Associated with Promoter-Specific and Global DNA Methylation Status in Ovarian Cancer
- (2008) A. Woloszynska-Read et al. CLINICAL CANCER RESEARCH
- The DNA demethylating agent 5-aza-2′-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma
- (2008) Atsushi Natsume et al. INTERNATIONAL JOURNAL OF CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started